Recently, a multimodal approach to oral squamous cell carcinoma (SCC) in cats, combining medical treatment and accelerated radiation therapy, showed a substantial outcome improvement in a small pilot study. Herein we retrospectively review 51 cats with unresectable, histologically confirmed oral SCC and a complete initial staging work‐up: cats in group A (n = 24) received medical anti‐angiogenic treatment consisting of bleomycin, piroxicam and thalidomide, cats in group B (n = 27) received the anti‐angiogenic treatment and concurrent accelerated hypofractionated radiation therapy with 48Gy delivered in 10 fractions. Overall median progression‐free interval (PFI) was poor with 70 days (95% CI: 48;93). In the irradiated cats (group B), however, PFI was significantly longer with 179 days (95% CI: 58;301) days, vs 30 days (95% CI: 23;38) in medically only treated cats (P < .001). Overall median overall survival (OS) was 89 days (95% CI: 55;124), again significantly longer in the irradiated cats (group B) with 136 (95% CI: 40;233) vs 38 days (95% CI: 23;54) (P < .001). In 8 of the 27 (29.6%) cats in group B, however, severe toxicity (grade 3) occurred. Neither onset nor severity of toxicity could be associated with any of the tested variables, including anatomic site, tumour size, clinical stage and duration of neoadjuvant medical treatment. Given the potential severe acute effects and the impact on quality of life after chemo‐radiotherapy, owners must be clearly informed about the risks of treatment. With the overall poor outcome and high occurrence of acute toxicity, we cannot recommend the use of this accelerated radiation protocol combined with anti‐angiogenic therapy for oral SCC in cats.

中文翻译：

---

加速次分割放疗和同时全身治疗后口腔鳞状细胞癌猫的毒性和预后。

最近，在小规模的先导研究中，将药物治疗与加速放射治疗相结合的猫口腔鳞状细胞癌（SCC）的多模式方法显示出明显的结局改善。在此我们回顾性回顾了51例经手术切除，经组织学证实为口腔鳞状细胞癌且已完成初步分期的猫：A组（n = 24）的猫接受了由博来霉素，吡罗昔康和沙利度胺组成的抗血管生成药物治疗，B组的猫（ n = 27）接受了抗血管生成治疗，并同时进行了加速的超分割放疗，其中48Gy分10次递送。总体中位数无进展间隔（PFI）为70天（95％CI：48; 93）。然而，在受辐照的猫（B组）中，PFI显着延长，为179天（95％CI：58； 301）天，而30天（95％CI：23； 72天）。P  <.001）。总体中位总体生存期（OS）为89天（95％CI：55; 124），与136天（95％CI：40; 233）的受辐照猫（B组）相比，38天（95％CI：95％CI ：）明显更长。 23; 54）（P <.001）。B组中的27只猫中有8只（29.6％）发生了严重的毒性反应（3级）。毒性的发作和严重性均与任何测试变量均无关，包括解剖部位，肿瘤大小，新辅助药物治疗的临床阶段和持续时间。考虑到潜在的严重急性影响以及放化疗后对生活质量的影响，必须明确告知所有人治疗的风险。由于总体效果差且急性毒性高发，因此我们不建议将这种加速放射方案与抗血管生成疗法联合用于猫的口腔SCC。